Literature DB >> 9091272

The place of quinolones in everyday clinical practice.

R C Moellering1.   

Abstract

The new fluoroquinolones have many attributes and relatively few drawbacks. As a result, they have been rapidly adopted for the treatment of serious bacterial infections. The currently available fluoroquinolones are particularly effective for the treatment of urinary tract infections, bacterial diarrhea, enteric fever, gonorrhea, chancroid, skin and soft tissue infections, acute and chronic gram-negative osteomyelitis, gram-negative pneumonias, serious infections due to a variety of gram-negative bacilli, and in the eradication of the meningococcal carrier state. As we learn more about the properties of these compounds, the number and variety of infections for which they are useful continues to expand.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9091272     DOI: 10.1159/000239492

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Correlation between quinolone uptakes by BCECs in vitro and brain-to-plasma concentration ratios in rats.

Authors:  X D Liu; D W Wang; L Xie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

2.  Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.

Authors:  S Marchand; C Pariat; S Bouquet; P Courtois; W Couet
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Authors:  P Kraiczy; J Weigand; T A Wichelhaus; P Heisig; H Backes; V Schäfer; G Acker; V Brade; K P Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Efficacy of pefloxacin in the treatment of patients with acute infectious diarrhoea.

Authors:  Biserka Troselj-Vukic; Ivica Poljak; Irena Milotic; Irena Slavic; Nebojsa Nikolic; Miro Morovic
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.